The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
10,876
Sort by:
Q Fever (Infectious Disease) - Drugs in Development, 2021
US$ 2,000.00
Q Fever (Infectious Disease) - Drugs in Development, 2021 SUMMARY Q Fever (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Q Fever pipeline landscape. The report provides...
April 2021
30 pages
Radiation Injury (Toxicology) - Drugs in Development, 2021
US$ 2,000.00
Radiation Injury (Toxicology) - Drugs in Development, 2021 SUMMARY Radiation Injury (Toxicology) - Drugs in Development, 2021 provides an overview of the Radiation Injury pipeline landscape. The repor...
April 2021
35 pages
Ras (EC 3.6.5.2) - Drugs in Development, 2021
US$ 3,000.00
Ras (EC 3.6.5.2) - Drugs in Development, 2021 SUMMARY Ras (EC 3.6.5.2) - Drugs in Development, 2021 provides in depth analysis on Ras (EC 3.6.5.2) targeted pipeline therapeutics. The report provides c...
April 2021
45 pages
Receptor Tyrosine Kinase (RTK) - Drugs in Development, 2021
US$ 3,000.00
Receptor Tyrosine Kinase (RTK) - Drugs in Development, 2021 SUMMARY Receptor Tyrosine Kinase (RTK) - Drugs in Development, 2021 provides in depth analysis on Receptor Tyrosine Kinase (RTK) targeted pi...
April 2021
30 pages
Retinoic Acid Receptor (RAR) - Drugs in Development, 2021
US$ 3,000.00
Retinoic Acid Receptor (RAR) - Drugs in Development, 2021 SUMMARY Retinoic Acid Receptor (RAR) - Drugs in Development, 2021 provides in depth analysis on Retinoic Acid Receptor (RAR) targeted pipeline...
April 2021
35 pages
Retinoid X Receptor (RXR) - Drugs in Development, 2021
US$ 3,000.00
Retinoid X Receptor (RXR) - Drugs in Development, 2021 SUMMARY Retinoid X Receptor (RXR) - Drugs in Development, 2021 provides in depth analysis on Retinoid X Receptor (RXR) targeted pipeline therapeu...
April 2021
30 pages
Retinopathy (Ophthalmology) - Drugs in Development, 2021
US$ 2,000.00
Retinopathy (Ophthalmology) - Drugs in Development, 2021 SUMMARY Retinopathy (Ophthalmology) - Drugs in Development, 2021 provides an overview of the Retinopathy pipeline landscape. The report provide...
April 2021
40 pages
Sarcoidosis (Immunology) - Drugs in Development, 2021
US$ 2,000.00
Sarcoidosis (Immunology) - Drugs in Development, 2021 SUMMARY Sarcoidosis (Immunology) - Drugs in Development, 2021 provides an overview of the Sarcoidosis pipeline landscape. The report provides comp...
April 2021
45 pages
